Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features

A retrospective cohort study

Ji Young Choe, Ji Y. Yun, Yoon K. Jeon, SeHoon Kim, Gyeongsin Park, Joo R. Huh, Sohee Oh, Ji E. Kim

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Regulation of tumor microenvironment is closely involved in the prognosis of Hodgkin lymphoma (HL). Indoleamine 2,3-dioxygenase (IDO) is an enzyme acting as immune modulator through suppression of T-cell immunity. This study aims to investigate role of IDO in the microenvironment of HL.Methods: A total of 121 cases of HL were enrolled to do immunohistochemistry for IDO, CD163, CD68, CD4, CD8, and FoxP3. Positivity was evaluated from area fractions or numbers of positive cells using automated image analyzer. Correlations between IDO expression and various cellular infiltrates and clinicopathologic parameters were examined and survival analyses were performed.Results: IDO was expressed in histiocytes, dendritic cells and some endothelial cells with variable degrees, but not in tumor cells. IDO positive cells were more frequently found in mixed cellularity type than other histologic types, and in cases with EBV+, high Ann Arbor stages, B symptoms, and high IPS (all p < 0.05). High IDO expression was associated with inferior survival (p < 0.001) and reflects an independent prognostic factor in nodular sclerosis HL.Conclusions: This is the first study suggesting that IDO is the principle immunomodulator and is involved to adverse clinical outcomes of HL.

Original languageEnglish
Article number335
JournalBMC Cancer
Volume14
Issue number1
DOIs
Publication statusPublished - 2014 May 15

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Stromal Cells
Hodgkin Disease
Cohort Studies
Retrospective Studies
Histiocytes
Tumor Microenvironment
Immunologic Factors
Sclerosis
Survival Analysis
Human Herpesvirus 4
Dendritic Cells
Immunity
Endothelial Cells
Cell Count
Immunohistochemistry
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Choe, Ji Young ; Yun, Ji Y. ; Jeon, Yoon K. ; Kim, SeHoon ; Park, Gyeongsin ; Huh, Joo R. ; Oh, Sohee ; Kim, Ji E. / Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features : A retrospective cohort study. In: BMC Cancer. 2014 ; Vol. 14, No. 1.
@article{16c1656070f448d38b414ca1cf40541a,
title = "Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: A retrospective cohort study",
abstract = "Background: Regulation of tumor microenvironment is closely involved in the prognosis of Hodgkin lymphoma (HL). Indoleamine 2,3-dioxygenase (IDO) is an enzyme acting as immune modulator through suppression of T-cell immunity. This study aims to investigate role of IDO in the microenvironment of HL.Methods: A total of 121 cases of HL were enrolled to do immunohistochemistry for IDO, CD163, CD68, CD4, CD8, and FoxP3. Positivity was evaluated from area fractions or numbers of positive cells using automated image analyzer. Correlations between IDO expression and various cellular infiltrates and clinicopathologic parameters were examined and survival analyses were performed.Results: IDO was expressed in histiocytes, dendritic cells and some endothelial cells with variable degrees, but not in tumor cells. IDO positive cells were more frequently found in mixed cellularity type than other histologic types, and in cases with EBV+, high Ann Arbor stages, B symptoms, and high IPS (all p < 0.05). High IDO expression was associated with inferior survival (p < 0.001) and reflects an independent prognostic factor in nodular sclerosis HL.Conclusions: This is the first study suggesting that IDO is the principle immunomodulator and is involved to adverse clinical outcomes of HL.",
author = "Choe, {Ji Young} and Yun, {Ji Y.} and Jeon, {Yoon K.} and SeHoon Kim and Gyeongsin Park and Huh, {Joo R.} and Sohee Oh and Kim, {Ji E.}",
year = "2014",
month = "5",
day = "15",
doi = "10.1186/1471-2407-14-335",
language = "English",
volume = "14",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features : A retrospective cohort study. / Choe, Ji Young; Yun, Ji Y.; Jeon, Yoon K.; Kim, SeHoon; Park, Gyeongsin; Huh, Joo R.; Oh, Sohee; Kim, Ji E.

In: BMC Cancer, Vol. 14, No. 1, 335, 15.05.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features

T2 - A retrospective cohort study

AU - Choe, Ji Young

AU - Yun, Ji Y.

AU - Jeon, Yoon K.

AU - Kim, SeHoon

AU - Park, Gyeongsin

AU - Huh, Joo R.

AU - Oh, Sohee

AU - Kim, Ji E.

PY - 2014/5/15

Y1 - 2014/5/15

N2 - Background: Regulation of tumor microenvironment is closely involved in the prognosis of Hodgkin lymphoma (HL). Indoleamine 2,3-dioxygenase (IDO) is an enzyme acting as immune modulator through suppression of T-cell immunity. This study aims to investigate role of IDO in the microenvironment of HL.Methods: A total of 121 cases of HL were enrolled to do immunohistochemistry for IDO, CD163, CD68, CD4, CD8, and FoxP3. Positivity was evaluated from area fractions or numbers of positive cells using automated image analyzer. Correlations between IDO expression and various cellular infiltrates and clinicopathologic parameters were examined and survival analyses were performed.Results: IDO was expressed in histiocytes, dendritic cells and some endothelial cells with variable degrees, but not in tumor cells. IDO positive cells were more frequently found in mixed cellularity type than other histologic types, and in cases with EBV+, high Ann Arbor stages, B symptoms, and high IPS (all p < 0.05). High IDO expression was associated with inferior survival (p < 0.001) and reflects an independent prognostic factor in nodular sclerosis HL.Conclusions: This is the first study suggesting that IDO is the principle immunomodulator and is involved to adverse clinical outcomes of HL.

AB - Background: Regulation of tumor microenvironment is closely involved in the prognosis of Hodgkin lymphoma (HL). Indoleamine 2,3-dioxygenase (IDO) is an enzyme acting as immune modulator through suppression of T-cell immunity. This study aims to investigate role of IDO in the microenvironment of HL.Methods: A total of 121 cases of HL were enrolled to do immunohistochemistry for IDO, CD163, CD68, CD4, CD8, and FoxP3. Positivity was evaluated from area fractions or numbers of positive cells using automated image analyzer. Correlations between IDO expression and various cellular infiltrates and clinicopathologic parameters were examined and survival analyses were performed.Results: IDO was expressed in histiocytes, dendritic cells and some endothelial cells with variable degrees, but not in tumor cells. IDO positive cells were more frequently found in mixed cellularity type than other histologic types, and in cases with EBV+, high Ann Arbor stages, B symptoms, and high IPS (all p < 0.05). High IDO expression was associated with inferior survival (p < 0.001) and reflects an independent prognostic factor in nodular sclerosis HL.Conclusions: This is the first study suggesting that IDO is the principle immunomodulator and is involved to adverse clinical outcomes of HL.

UR - http://www.scopus.com/inward/record.url?scp=84901239041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901239041&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-14-335

DO - 10.1186/1471-2407-14-335

M3 - Article

VL - 14

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 335

ER -